{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:59:36Z","timestamp":1760853576841,"version":"3.38.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["1RC1 DA028477","CHE-95-31247","1S10RR11962-01"],"award-info":[{"award-number":["1RC1 DA028477","CHE-95-31247","1S10RR11962-01"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Harry S. Truman Memorial Veterans' Hospital"},{"name":"the University of Missouri Life Sciences Mission Enhancement Program"},{"name":"NSF"},{"name":"NIH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.nucmedbio.2011.10.001","type":"journal-article","created":{"date-parts":[[2011,12,14]],"date-time":"2011-12-14T14:10:46Z","timestamp":1323871846000},"page":"401-414","source":"Crossref","is-referenced-by-count":14,"title":["Synthesis, radioiodination and in vitro and in vivo sigma receptor studies of N-1-allyl-N\u00b4-4-phenethylpiperazine analogs"],"prefix":"10.1016","volume":"39","author":[{"given":"Susan Z.","family":"Lever","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-Hsien","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily A.","family":"Fergason-Cantrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry L.","family":"Carmack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa D.","family":"Watkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Lever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0005","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2174\/157015908787386113","article-title":"Pharmacology and therapeutic potential of sigma1 receptor ligands","volume":"6","author":"Cobos","year":"2008","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharmthera.2009.07.001","article-title":"The pharmacology of sigma-1 receptors","volume":"124","author":"Maurice","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1517\/14728222.2011.560837","article-title":"Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders","volume":"15","author":"Hayashi","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1254\/jphs.CR0050032","article-title":"The sigma1 protein as a target for the non-genomic effects of neuro(active)steroids: molecular, physiological, and behavioral aspects","volume":"100","author":"Monnet","year":"2006","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0025","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1126\/science.1166127","article-title":"The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator","volume":"323","author":"Fontanilla","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/14728222.12.1.45","article-title":"An update on the development of drugs for neuropsychiatric disorders: focusing on the \u03c31 receptor ligand","volume":"12","author":"Hayashi","year":"2008","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(03)01723-0","article-title":"\u03c3 receptors: potential medications development target for anti-cocaine agents","volume":"469","author":"Matsumoto","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0040","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.2174\/156802611795371323","article-title":"Sigma receptors and cocaine abuse","volume":"11","author":"Narayanan","year":"2011","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0045","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.pbb.2010.11.016","article-title":"SA 4503 attenuates cocaine-induced hyperactivity and enhances methamphetamine substitution for a cocaine discriminative stimulus","volume":"97","author":"Rodvelt","year":"2011","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0050","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/npp.2011.5","article-title":"Activation of \u03c3-receptors induces binge-like drinking in Sardinian alcohol-preferring rats","volume":"36","author":"Sabino","year":"2011","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0055","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1158\/0008-5472.CAN-03-2329","article-title":"Sigma receptors and cancer: possible involvement of ion channels","volume":"64","author":"Aydar","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0060","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.2174\/138161206778559614","article-title":"Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals","volume":"12","author":"Hashimoto","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-9-298","article-title":"The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine","volume":"9","author":"Hornick","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/138161207779313740","article-title":"Imaging sigma receptors: applications in drug development","volume":"13","author":"Collier","year":"2007","journal-title":"Curr Pharm Design"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0075","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1021\/jm960720+","article-title":"Halogenated 4-(phenoxymethyl)piperidines as potential radiolabeled probes for sigma-1 receptors: in vivo evaluation of [123I]-1-(iodopropen-2-yl)-4-[(4-cyanophenoxy)methyl]piperidine","volume":"40","author":"Waterhouse","year":"1997","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0080","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/syn.20281","article-title":"[123I]TPCNE-a novel SPET tracer for the sigma-1 receptor: first human studies and in vivo haloperidol challenge","volume":"60","author":"Stone","year":"2006","journal-title":"Synapse"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0085","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.nucmedbio.2005.10.007","article-title":"In vivo evaluation in rats of [18F]-(2-fluoroethyl)-4-[(4-cyanophenoxy)methyl]piperidine as a potential radiotracer for PET assessment of CNS sigma-1 receptors","volume":"33","author":"Waterhouse","year":"2006","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0969-8051(00)00081-0","article-title":"In vivo evaluation of [11C]SA4503 as a PET ligand for mapping CNS sigma1 receptors","volume":"27","author":"Kawamura","year":"2000","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0095","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/syn.20253","article-title":"\u03c31 and \u03c32 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503","volume":"59","author":"Lever","year":"2006","journal-title":"Synapse"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0100","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/BF03026824","article-title":"A feasibility study of [11C]SA4503-PET for evaluating sigma1 receptor occupancy by neuroleptics: the binding of haloperidol to sigma1 and dopamine D2-like receptors","volume":"20","author":"Ishiwata","year":"2006","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0105","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.biopsych.2007.04.001","article-title":"High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503","volume":"62","author":"Ishikawa","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroimage.2006.11.055","article-title":"Mapping of human cerebral sigma1 receptors using positron emission tomography and [11C]SA4503","volume":"35","author":"Sakata","year":"2007","journal-title":"Neuroimage"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/syn.20001","article-title":"Evaluation of [18F]fluorinated sigma receptor ligands in the conscious monkey brain","volume":"52","author":"Elsinga","year":"2004","journal-title":"Synapse"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0120","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1017\/S1461145709990204","article-title":"High occupancy of \u03c31 receptors in human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503","volume":"12","author":"Ishikawa","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0125","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.mibio.2003.09.014","article-title":"Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents","volume":"5","author":"Waterhouse","year":"2003","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0130","first-page":"246","article-title":"Synthesis, binding studies and biodistribution of novel radioiodinated sigma-1 receptor ligands","volume":"48","author":"Lever","year":"2007","journal-title":"J Nucl Med"},{"year":"2007","author":"Lever","article-title":"Cocaine occupancy of sigma-1 receptors in vivo","key":"10.1016\/j.nucmedbio.2011.10.001_bb0135"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0140","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.bmcl.2003.09.083","article-title":"Conformationally-flexible benzamide analogues as dopamine D3 and sigma2 receptor ligands","volume":"14","author":"Mach","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0145","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0969-8051(95)02074-8","article-title":"Synthesis and in vivo studies of a selective ligand for the dopamine transporter: 3\u03b2-(4-[125I]iodophenyl) tropan-2\u03b2-carboxylic acid isopropyl ester ([125I]RTI-121)","volume":"23","author":"Lever","year":"1996","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0150","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1021\/bc00014a012","article-title":"Vinylstannylated alkylating agents as prosthetic groups for radioiodination of small molecules: design, synthesis, and application to iodoallyl analogues of spiperone and diprenorphine","volume":"3","author":"Musachio","year":"1992","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0155","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1021\/jm00361a003","article-title":"New selenium-75 labeled radiopharmaceuticals: selenonium analogues of dopamine","volume":"26","author":"Sadek","year":"1983","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0160","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.bmc.2007.10.037","article-title":"Synthesis and structure-activity relationships of N-(3-phenylpropyl)-N\u00b4-benzylpiperazines: potent ligands for \u03c31 and \u03c32 receptors","volume":"16","author":"Nahas","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0165","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0170","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1021\/jm0700013","article-title":"Indium-labeled macrocyclic conjugates of naltrindole: high affinity radioligands for in vivo studies of peripheral \u03b4 opioid receptors","volume":"50","author":"Duval","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0175","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0026-895X(25)08626-2","article-title":"Selective labeling of the dopamine transporter by the high affinity ligand 3\u03b2-(4-[125I]Iodophenyl)tropane-2 \u03b2-carboxylic acid isopropyl ester","volume":"47","author":"Boja","year":"1995","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0180","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/sj.bjp.0706108","article-title":"Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors","volume":"144","author":"Hirano","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0185","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0014-2999(90)94155-Q","article-title":"[3H]nisoxetine: a new radioligand for norepinephrine uptake sites in brain","volume":"191","author":"Tejani-Butt","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0190","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/syn.20103","article-title":"Phenytoin differentially modulates the affinity of agonist and antagonist ligands for \u03c31 receptors of guinea pig brain","volume":"55","author":"Cobos","year":"2005","journal-title":"Synapse"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0195","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0014-2999(95)00383-V","article-title":"Discrepancies in characterization of \u03c3 sites in the mouse central nervous system","volume":"285","author":"Kov\u00e1cs","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0200","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0028-3908(01)00116-2","article-title":"Rimcazole analogs attenuate the convulsive effects of cocaine: correlation with binding to sigma receptors rather than dopamine transporters","volume":"41","author":"Matsumoto","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0205","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0922-4106(92)90153-M","article-title":"Characterization of the binding of [3H](+)-pentazocine to sigma recognition sites in guinea pig brain","volume":"227","author":"DeHaven-Hudkins","year":"1992","journal-title":"Eur J Pharmacol"},{"issue":"Suppl1","key":"10.1016\/j.nucmedbio.2011.10.001_bb0210","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1007\/BF02245006","article-title":"Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors","volume":"112","author":"Leysen","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0215","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0014-2999(95)00208-3","article-title":"Characterization of two novel \u03c3 receptor ligands: antidystonic effects in rats suggest \u03c3 receptor antagonism","volume":"280","author":"Matsumoto","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0220","first-page":"1041","article-title":"Synthesis and in vivo evaluation of 2 high-affinity 76Br-labeled \u03c32-receptor ligands","volume":"47","author":"Rowland","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0225","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0922-4106(94)90115-5","article-title":"Rat liver and kidney contain high densities of \u03c31 and \u03c32 receptors: characterization by ligand binding and photoaffinity labeling","volume":"268","author":"Hellewell","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0230","first-page":"764","article-title":"Cytochrome P4502D6 catalyzes O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine","volume":"26","author":"Obach","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0235","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/npp.2008.110","article-title":"Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition","volume":"34","author":"Miksys","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0240","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0022-3565(24)29567-7","article-title":"In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats","volume":"297","author":"Baumann","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nucmedbio.2011.10.001_bb0245","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s002130051091","article-title":"Occupancy of striatal D2-like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic","volume":"146","author":"Gr\u00fcnder","year":"1999","journal-title":"Psychopharmacology"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805111002332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805111002332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T20:31:31Z","timestamp":1742070691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805111002332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0969805111002332"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2011.10.001","relation":{},"ISSN":["0969-8051"],"issn-type":[{"type":"print","value":"0969-8051"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}